Barclays PLC Increases Position in Pyxis Oncology, Inc. (NASDAQ:PYXS)

Barclays PLC boosted its stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 275.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,089 shares of the company’s stock after buying an additional 46,997 shares during the quarter. Barclays PLC’s holdings in Pyxis Oncology were worth $235,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of PYXS. Jacobs Levy Equity Management Inc. bought a new stake in Pyxis Oncology during the 3rd quarter valued at $1,405,000. Bank of New York Mellon Corp raised its holdings in shares of Pyxis Oncology by 92.2% during the second quarter. Bank of New York Mellon Corp now owns 311,630 shares of the company’s stock worth $1,031,000 after purchasing an additional 149,522 shares during the last quarter. abrdn plc lifted its position in Pyxis Oncology by 28.9% during the third quarter. abrdn plc now owns 913,045 shares of the company’s stock valued at $3,351,000 after purchasing an additional 204,742 shares during the period. Millennium Management LLC raised its position in Pyxis Oncology by 125.3% during the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock valued at $4,425,000 after acquiring an additional 743,499 shares in the last quarter. Finally, Blue Owl Capital Holdings LP purchased a new stake in Pyxis Oncology during the second quarter worth $3,462,000. 39.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Pyxis Oncology news, CFO Pamela Ann Connealy purchased 88,850 shares of Pyxis Oncology stock in a transaction dated Tuesday, November 26th. The shares were acquired at an average price of $1.96 per share, with a total value of $174,146.00. Following the completion of the transaction, the chief financial officer now owns 1,199,143 shares of the company’s stock, valued at $2,350,320.28. This trade represents a 8.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 9.80% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on PYXS shares. Stephens assumed coverage on shares of Pyxis Oncology in a research report on Friday, November 8th. They set an “overweight” rating and a $13.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $5.00 price objective (down previously from $7.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 target price (down from $10.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. Finally, William Blair downgraded shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 21st. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $9.43.

Pyxis Oncology Trading Up 0.6 %

Shares of PYXS opened at $1.70 on Monday. The company’s 50-day moving average price is $2.56 and its 200 day moving average price is $3.14. The firm has a market cap of $101.09 million, a P/E ratio of -1.65 and a beta of 1.00. Pyxis Oncology, Inc. has a 12-month low of $1.49 and a 12-month high of $6.85.

Pyxis Oncology Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.